Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Zoetis Inc. (ZTS) trades at a EV/EBITDA of 10.4×. Over the past ten years it has ranged from 9.4× (October 2026) to 39.4× (December 2021); the current reading is higher than 4% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 12.6× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 15.7× (23.16%)
FY2024 20.4× (21.48%)
FY2023 26.0× 18.57%
FY2022 21.9× (41.81%)
FY2021 37.6× 22.00%
FY2020 30.8× 10.83%
FY2019 27.8× 33.13%
FY2018 20.9× 3.29%
FY2017 20.2× 9.10%
FY2016 18.5× (41.79%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.6× (32.91%)
Mar 2026 14.4× (8.29%)
Dec 2025 15.7× (11.73%)
Sep 2025 17.7× (4.97%)
42 more quarters

Against its own ten years

Low 9.4× High 39.4×
Ten-year median 23.6×
Current reading's percentile 4

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. 10.4×
TAK Takeda Pharmaceutical Co. compare 10.8×
VTRS Viatris Inc. compare 12.6×
HLN Haleon PLC Sponsored ADR compare 13.3×
UTHR United Therapeutics Corporation compare 13.6×
NBIX Neurocrine Biosciences, Inc. compare 16.7×
RDY Dr. Reddy's Laboratories Ltd compare 17.0×
ELAN Elanco Animal Health Incorporated compare 19.6×
TEVA Teva Pharmaceutical Industries Ltd. compare 24.5×
Drug Manufacturers Specialty & Generic industry median 12.6×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ZTS